APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oral Vaccine for Human

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Oral Vaccine for Human Market Analysis and Forecast 2026-2032

30 December 2025197 pages

Choose your research edition.

Industry ResearchOral Vaccine for Human Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral Vaccine for Human Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Oral Vaccine for Human Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral Vaccine for Human Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral Vaccine for Human Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Oral Vaccine for Human market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Oral Vaccine for Human is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Oral Vaccine for Human is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Oral Vaccine for Human is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Oral Vaccine for Human is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Oral Vaccine for Human include Bibcol, Bio-Med, EuBiologics, Halfkin Bio-Pharmaceuticals, Panacea Biotec Ltd, PaxVax, Serum Institute, Vabiotech and Valneva, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Oral Vaccine for Human, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Oral Vaccine for Human, also provides the sales of main regions and countries. Of the upcoming market potential for Oral Vaccine for Human, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Oral Vaccine for Human sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Oral Vaccine for Human market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Oral Vaccine for Human sales, projected growth trends, production technology, application and end-user industry.

Oral Vaccine for Human Segment by Company

Bibcol

Bio-Med

EuBiologics

Halfkin Bio-Pharmaceuticals

Panacea Biotec Ltd

PaxVax

Serum Institute

Vabiotech

Valneva

Tiantan Biological

GSK

Merck

Sanofi

Shanghai United Cell

Lanzhou Institute

Oral Vaccine for Human Segment by Type

Cholera Vaccine

Oral Polio Vaccine

Rotavirus Vaccine

Other

Oral Vaccine for Human Segment by Application

Public

Private

Oral Vaccine for Human Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Vaccine for Human market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral Vaccine for Human and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Vaccine for Human.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Oral Vaccine for Human in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Oral Vaccine for Human manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oral Vaccine for Human sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Oral Vaccine for Human Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Cholera Vaccine Major Manufacturers Table 3. Oral Polio Vaccine Major Manufacturers Table 4. Rotavirus Vaccine Major Manufacturers Table 5. Other Major Manufacturers Table 6. Global Oral Vaccine for Human Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Public Major Manufacturers Table 8. Private Major Manufacturers Table 9. Oral Vaccine for Human Industry Trends Table 10. Oral Vaccine for Human Industry Drivers Table 11. Oral Vaccine for Human Industry Opportunities and Challenges Table 12. Oral Vaccine for Human Industry Restraints Table 13. Global Oral Vaccine for Human Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 14. Global Oral Vaccine for Human Revenue by Region (2021-2026) & (US$ Million) Table 15. Global Oral Vaccine for Human Revenue by Region (2027-2032) & (US$ Million) Table 16. Global Oral Vaccine for Human Revenue Market Share by Region (2021-2026) Table 17. Global Oral Vaccine for Human Revenue Market Share by Region (2027-2032) Table 18. Global Oral Vaccine for Human Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 19. Global Oral Vaccine for Human Sales by Region (2021-2026) & (K Units) Table 20. Global Oral Vaccine for Human Sales by Region (2027-2032) & (K Units) Table 21. Global Oral Vaccine for Human Sales Market Share by Region (2021-2026) Table 22. Global Oral Vaccine for Human Sales Market Share by Region (2027-2032) Table 23. Global Oral Vaccine for Human Revenue by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Oral Vaccine for Human Revenue Market Share by Manufacturers (2021-2026) Table 25. Global Oral Vaccine for Human Sales by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Oral Vaccine for Human Sales Market Share by Manufacturers (2021-2026) Table 27. Global Oral Vaccine for Human Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 28. Global Oral Vaccine for Human Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 29. Global Oral Vaccine for Human Key Manufacturers Manufacturing Sites & Headquarters Table 30. Global Oral Vaccine for Human Manufacturers, Product Type & Application Table 31. Global Oral Vaccine for Human Manufacturers' Establishment Date Table 32. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 33. Global Oral Vaccine for Human by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 34. Global Oral Vaccine for Human Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Oral Vaccine for Human Revenue by Type (2021-2026) & (US$ Million) Table 36. Global Oral Vaccine for Human Revenue by Type (2027-2032) & (US$ Million) Table 37. Global Oral Vaccine for Human Revenue Market Share by Type (2021-2026) Table 38. Global Oral Vaccine for Human Revenue Market Share by Type (2027-2032) Table 39. Global Oral Vaccine for Human Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 40. Global Oral Vaccine for Human Sales by Type (2021-2026) & (K Units) Table 41. Global Oral Vaccine for Human Sales by Type (2027-2032) & (K Units) Table 42. Global Oral Vaccine for Human Sales Market Share by Type (2021-2026) Table 43. Global Oral Vaccine for Human Sales Market Share by Type (2027-2032) Table 44. Global Oral Vaccine for Human Price by Type (2021-2026) & (US$/Unit) Table 45. Global Oral Vaccine for Human Price by Type (2027-2032) & (US$/Unit) Table 46. Global Oral Vaccine for Human Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Oral Vaccine for Human Revenue by Application (2021-2026) & (US$ Million) Table 48. Global Oral Vaccine for Human Revenue by Application (2027-2032) & (US$ Million) Table 49. Global Oral Vaccine for Human Revenue Market Share by Application (2021-2026) Table 50. Global Oral Vaccine for Human Revenue Market Share by Application (2027-2032) Table 51. Global Oral Vaccine for Human Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 52. Global Oral Vaccine for Human Sales by Application (2021-2026) & (K Units) Table 53. Global Oral Vaccine for Human Sales by Application (2027-2032) & (K Units) Table 54. Global Oral Vaccine for Human Sales Market Share by Application (2021-2026) Table 55. Global Oral Vaccine for Human Sales Market Share by Application (2027-2032) Table 56. Global Oral Vaccine for Human Price by Application (2021-2026) & (US$/Unit) Table 57. Global Oral Vaccine for Human Price by Application (2027-2032) & (US$/Unit) Table 58. Bibcol Company Information Table 59. Bibcol Business Overview Table 60. Bibcol Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Bibcol Oral Vaccine for Human Product Portfolio Table 62. Bibcol Recent Development Table 63. Bio-Med Company Information Table 64. Bio-Med Business Overview Table 65. Bio-Med Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Bio-Med Oral Vaccine for Human Product Portfolio Table 67. Bio-Med Recent Development Table 68. EuBiologics Company Information Table 69. EuBiologics Business Overview Table 70. EuBiologics Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. EuBiologics Oral Vaccine for Human Product Portfolio Table 72. EuBiologics Recent Development Table 73. Halfkin Bio-Pharmaceuticals Company Information Table 74. Halfkin Bio-Pharmaceuticals Business Overview Table 75. Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Product Portfolio Table 77. Halfkin Bio-Pharmaceuticals Recent Development Table 78. Panacea Biotec Ltd Company Information Table 79. Panacea Biotec Ltd Business Overview Table 80. Panacea Biotec Ltd Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Panacea Biotec Ltd Oral Vaccine for Human Product Portfolio Table 82. Panacea Biotec Ltd Recent Development Table 83. PaxVax Company Information Table 84. PaxVax Business Overview Table 85. PaxVax Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. PaxVax Oral Vaccine for Human Product Portfolio Table 87. PaxVax Recent Development Table 88. Serum Institute Company Information Table 89. Serum Institute Business Overview Table 90. Serum Institute Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Serum Institute Oral Vaccine for Human Product Portfolio Table 92. Serum Institute Recent Development Table 93. Vabiotech Company Information Table 94. Vabiotech Business Overview Table 95. Vabiotech Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Vabiotech Oral Vaccine for Human Product Portfolio Table 97. Vabiotech Recent Development Table 98. Valneva Company Information Table 99. Valneva Business Overview Table 100. Valneva Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Valneva Oral Vaccine for Human Product Portfolio Table 102. Valneva Recent Development Table 103. Tiantan Biological Company Information Table 104. Tiantan Biological Business Overview Table 105. Tiantan Biological Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Tiantan Biological Oral Vaccine for Human Product Portfolio Table 107. Tiantan Biological Recent Development Table 108. GSK Company Information Table 109. GSK Business Overview Table 110. GSK Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. GSK Oral Vaccine for Human Product Portfolio Table 112. GSK Recent Development Table 113. Merck Company Information Table 114. Merck Business Overview Table 115. Merck Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Merck Oral Vaccine for Human Product Portfolio Table 117. Merck Recent Development Table 118. Sanofi Company Information Table 119. Sanofi Business Overview Table 120. Sanofi Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Sanofi Oral Vaccine for Human Product Portfolio Table 122. Sanofi Recent Development Table 123. Shanghai United Cell Company Information Table 124. Shanghai United Cell Business Overview Table 125. Shanghai United Cell Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Shanghai United Cell Oral Vaccine for Human Product Portfolio Table 127. Shanghai United Cell Recent Development Table 128. Lanzhou Institute Company Information Table 129. Lanzhou Institute Business Overview Table 130. Lanzhou Institute Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Lanzhou Institute Oral Vaccine for Human Product Portfolio Table 132. Lanzhou Institute Recent Development Table 133. North America Oral Vaccine for Human Revenue by Type (2021-2026) & (US$ Million) Table 134. North America Oral Vaccine for Human Revenue by Type (2027-2032) & (US$ Million) Table 135. North America Oral Vaccine for Human Sales by Type (2021-2026) & (K Units) Table 136. North America Oral Vaccine for Human Sales by Type (2027-2032) & (K Units) Table 137. North America Oral Vaccine for Human Sales Price by Type (2021-2026) & (US$/Unit) Table 138. North America Oral Vaccine for Human Sales Price by Type (2027-2032) & (US$/Unit) Table 139. North America Oral Vaccine for Human Revenue by Application (2021-2026) & (US$ Million) Table 140. North America Oral Vaccine for Human Revenue by Application (2027-2032) & (US$ Million) Table 141. North America Oral Vaccine for Human Sales by Application (2021-2026) & (K Units) Table 142. North America Oral Vaccine for Human Sales by Application (2027-2032) & (K Units) Table 143. North America Oral Vaccine for Human Sales Price by Application (2021-2026) & (US$/Unit) Table 144. North America Oral Vaccine for Human Sales Price by Application (2027-2032) & (US$/Unit) Table 145. North America Oral Vaccine for Human Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 146. North America Oral Vaccine for Human Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 147. North America Oral Vaccine for Human Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 148. North America Oral Vaccine for Human Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 149. North America Oral Vaccine for Human Sales by Country (2021-2026) & (K Units) Table 150. North America Oral Vaccine for Human Sales by Country (2027-2032) & (K Units) Table 151. North America Oral Vaccine for Human Sales Price by Country (2021-2026) & (US$/Unit) Table 152. North America Oral Vaccine for Human Sales Price by Country (2027-2032) & (US$/Unit) Table 153. United States Oral Vaccine for Human Revenue (2021-2032) & (US$ Million) Table 154. Canada Oral Vaccine for Human Revenue (2021-2032) & (US$ Million) Table 155. Europe Oral Vaccine for Human Revenue by Type (2021-2026) & (US$ Million) Table 156. Europe Oral Vaccine for Human Revenue by Type (2027-2032) & (US$ Million) Table 157. Europe Oral Vaccine for Human Sales by Type (2021-2026) & (K Units) Table 158. Europe Oral Vaccine for Human Sales by Type (2027-2032) & (K Units) Table 159. Europe Oral Vaccine for Human Sales Price by Type (2021-2026) & (US$/Unit) Table 160. Europe Oral Vaccine for Human Sales Price by Type (2027-2032) & (US$/Unit) Table 161. Europe Oral Vaccine for Human Revenue by Application (2021-2026) & (US$ Million) Table 162. Europe Oral Vaccine for Human Revenue by Application (2027-2032) & (US$ Million) Table 163. Europe Oral Vaccine for Human Sales by Application (2021-2026) & (K Units) Table 164. Europe Oral Vaccine for Human Sales by Application (2027-2032) & (K Units) Table 165. Europe Oral Vaccine for Human Sales Price by Application (2021-2026) & (US$/Unit) Table 166. Europe Oral Vaccine for Human Sales Price by Application (2027-2032) & (US$/Unit) Table 167. Europe Oral Vaccine for Human Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 168. Europe Oral Vaccine for Human Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 169. Europe Oral Vaccine for Human Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 170. Europe Oral Vaccine for Human Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 171. Europe Oral Vaccine for Human Sales by Country (2021-2026) & (K Units) Table 172. Europe Oral Vaccine for Human Sales by Country (2027-2032) & (K Units) Table 173. Europe Oral Vaccine for Human Sales Price by Country (2021-2026) & (US$/Unit) Table 174. Europe Oral Vaccine for Human Sales Price by Country (2027-2032) & (US$/Unit) Table 175. Germany Oral Vaccine for Human Revenue (2021-2032) & (US$ Million) Table 176. France Oral Vaccine for Human Revenue (2021-2032) & (US$ Million) Table 177. U.K. Oral Vaccine for Human Revenue (2021-2032) & (US$ Million) Table 178. Italy Oral Vaccine for Human Revenue (2021-2032) & (US$ Million) Table 179. Netherlands Oral Vaccine for Human Revenue (2021-2032) & (US$ Million) Table 180. China Oral Vaccine for Human Revenue by Type (2021-2026) & (US$ Million) Table 181. China Oral Vaccine for Human Revenue by Type (2027-2032) & (US$ Million) Table 182. China Oral Vaccine for Human Sales by Type (2021-2026) & (K Units) Table 183. China Oral Vaccine for Human Sales by Type (2027-2032) & (K Units) Table 184. China Oral Vaccine for Human Sales Price by Type (2021-2026) & (US$/Unit) Table 185. China Oral Vaccine for Human Sales Price by Type (2027-2032) & (US$/Unit) Table 186. China Oral Vaccine for Human Revenue by Application (2021-2026) & (US$ Million) Table 187. China Oral Vaccine for Human Revenue by Application (2027-2032) & (US$ Million) Table 188. China Oral Vaccine for Human Sales by Application (2021-2026) & (K Units) Table 189. China Oral Vaccine for Human Sales by Application (2027-2032) & (K Units) Table 190. China Oral Vaccine for Human Sales Price by Application (2021-2026) & (US$/Unit) Table 191. China Oral Vaccine for Human Sales Price by Application (2027-2032) & (US$/Unit) Table 192. Asia Oral Vaccine for Human Revenue by Type (2021-2026) & (US$ Million) Table 193. Asia Oral Vaccine for Human Revenue by Type (2027-2032) & (US$ Million) Table 194. Asia Oral Vaccine for Human Sales by Type (2021-2026) & (K Units) Table 195. Asia Oral Vaccine for Human Sales by Type (2027-2032) & (K Units) Table 196. Asia Oral Vaccine for Human Sales Price by Type (2021-2026) & (US$/Unit) Table 197. Asia Oral Vaccine for Human Sales Price by Type (2027-2032) & (US$/Unit) Table 198. Asia Oral Vaccine for Human Revenue by Application (2021-2026) & (US$ Million) Table 199. Asia Oral Vaccine for Human Revenue by Application (2027-2032) & (US$ Million) Table 200. Asia Oral Vaccine for Human Sales by Application (2021-2026) & (K Units) Table 201. Asia Oral Vaccine for Human Sales by Application (2027-2032) & (K Units) Table 202. Asia Oral Vaccine for Human Sales Price by Application (2021-2026) & (US$/Unit) Table 203. Asia Oral Vaccine for Human Sales Price by Application (2027-2032) & (US$/Unit) Table 204. Asia Oral Vaccine for Human Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 205. Asia Oral Vaccine for Human Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 206. Asia Oral Vaccine for Human Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 207. Asia Oral Vaccine for Human Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 208. Asia Oral Vaccine for Human Sales by Country (2021-2026) & (K Units) Table 209. Asia Oral Vaccine for Human Sales by Country (2027-2032) & (K Units) Table 210. Asia Oral Vaccine for Human Sales Price by Country (2021-2026) & (US$/Unit) Table 211. Asia Oral Vaccine for Human Sales Price by Country (2027-2032) & (US$/Unit) Table 212. Japan Oral Vaccine for Human Revenue (2021-2032) & (US$ Million) Table 213. South Korea Oral Vaccine for Human Revenue (2021-2032) & (US$ Million) Table 214. India Oral Vaccine for Human Revenue (2021-2032) & (US$ Million) Table 215. Australia Oral Vaccine for Human Revenue (2021-2032) & (US$ Million) Table 216. China Taiwan Oral Vaccine for Human Revenue (2021-2032) & (US$ Million) Table 217. Southeast Asia Oral Vaccine for Human Revenue (2021-2032) & (US$ Million) Table 218. SAMEA Oral Vaccine for Human Revenue by Type (2021-2026) & (US$ Million) Table 219. SAMEA Oral Vaccine for Human Revenue by Type (2027-2032) & (US$ Million) Table 220. SAMEA Oral Vaccine for Human Sales by Type (2021-2026) & (K Units) Table 221. SAMEA Oral Vaccine for Human Sales by Type (2027-2032) & (K Units) Table 222. SAMEA Oral Vaccine for Human Sales Price by Type (2021-2026) & (US$/Unit) Table 223. SAMEA Oral Vaccine for Human Sales Price by Type (2027-2032) & (US$/Unit) Table 224. SAMEA Oral Vaccine for Human Revenue by Application (2021-2026) & (US$ Million) Table 225. SAMEA Oral Vaccine for Human Revenue by Application (2027-2032) & (US$ Million) Table 226. SAMEA Oral Vaccine for Human Sales by Application (2021-2026) & (K Units) Table 227. SAMEA Oral Vaccine for Human Sales by Application (2027-2032) & (K Units) Table 228. SAMEA Oral Vaccine for Human Sales Price by Application (2021-2026) & (US$/Unit) Table 229. SAMEA Oral Vaccine for Human Sales Price by Application (2027-2032) & (US$/Unit) Table 230. SAMEA Oral Vaccine for Human Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 231. SAMEA Oral Vaccine for Human Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 232. SAMEA Oral Vaccine for Human Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 233. SAMEA Oral Vaccine for Human Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 234. SAMEA Oral Vaccine for Human Sales by Country (2021-2026) & (K Units) Table 235. SAMEA Oral Vaccine for Human Sales by Country (2027-2032) & (K Units) Table 236. SAMEA Oral Vaccine for Human Sales Price by Country (2021-2026) & (US$/Unit) Table 237. SAMEA Oral Vaccine for Human Sales Price by Country (2027-2032) & (US$/Unit) Table 238. Brazil Oral Vaccine for Human Revenue (2021-2032) & (US$ Million) Table 239. Argentina Oral Vaccine for Human Revenue (2021-2032) & (US$ Million) Table 240. Chile Oral Vaccine for Human Revenue (2021-2032) & (US$ Million) Table 241. Colombia Oral Vaccine for Human Revenue (2021-2032) & (US$ Million) Table 242. Peru Oral Vaccine for Human Revenue (2021-2032) & (US$ Million) Table 243. Saudi Arabia Oral Vaccine for Human Revenue (2021-2032) & (US$ Million) Table 244. Israel Oral Vaccine for Human Revenue (2021-2032) & (US$ Million) Table 245. UAE Oral Vaccine for Human Revenue (2021-2032) & (US$ Million) Table 246. Turkey Oral Vaccine for Human Revenue (2021-2032) & (US$ Million) Table 247. Iran Oral Vaccine for Human Revenue (2021-2032) & (US$ Million) Table 248. Egypt Oral Vaccine for Human Revenue (2021-2032) & (US$ Million) Table 249. Key Raw Materials Table 250. Raw Materials Key Suppliers Table 251. Oral Vaccine for Human Distributors List Table 252. Oral Vaccine for Human Customers List Table 253. Research Programs/Design for This Report Table 254. Authors List of This Report Table 255. Secondary Sources Table 256. Primary Sources List of Figures Figure 1. Oral Vaccine for Human Image Figure 2. Global Oral Vaccine for Human Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oral Vaccine for Human Market Size Share 2021 VS 2025 VS 2032 Figure 4. Cholera Vaccine Image Figure 5. Oral Polio Vaccine Image Figure 6. Rotavirus Vaccine Image Figure 7. Other Image Figure 8. Global Oral Vaccine for Human Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Oral Vaccine for Human Market Size Share 2021 VS 2025 VS 2032 Figure 10. Public Image Figure 11. Private Image Figure 12. Global Oral Vaccine for Human Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Oral Vaccine for Human Revenue (2021-2032) & (US$ Million) Figure 14. Global Oral Vaccine for Human Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 15. Global Oral Vaccine for Human Revenue Market Share by Region: 2025 Versus 2032 Figure 16. Global Oral Vaccine for Human Revenue Market Share by Region (2021-2032) Figure 17. Global Oral Vaccine for Human Sales (2021-2032) & (K Units) Figure 18. Global Oral Vaccine for Human Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 19. Global Oral Vaccine for Human Sales Market Share by Region (2021-2032) Figure 20. US & Canada & Mexico Oral Vaccine for Human Sales YoY (2021-2032) & (K Units) Figure 21. Europe Oral Vaccine for Human Sales YoY (2021-2032) & (K Units) Figure 22. China Oral Vaccine for Human Sales YoY (2021-2032) & (K Units) Figure 23. Asia (Excluding China) Oral Vaccine for Human Sales YoY (2021-2032) & (K Units) Figure 24. South America, Middle East and Africa Oral Vaccine for Human Sales YoY (2021-2032) & (K Units) Figure 25. Global Oral Vaccine for Human Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 26. Global Oral Vaccine for Human Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 27. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 28. Global Oral Vaccine for Human Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Oral Vaccine for Human Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 30. Global Oral Vaccine for Human Revenue Market Share by Type (2021-2032) Figure 31. Global Oral Vaccine for Human Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 32. Global Oral Vaccine for Human Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Oral Vaccine for Human Sales Market Share by Type (2021-2032) Figure 34. Global Oral Vaccine for Human Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 35. Global Oral Vaccine for Human Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 36. Global Oral Vaccine for Human Revenue Market Share by Application (2021-2032) Figure 37. Global Oral Vaccine for Human Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 38. Global Oral Vaccine for Human Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Oral Vaccine for Human Sales Market Share by Application (2021-2032) Figure 40. North America Oral Vaccine for Human Revenue Share by Type (2021-2032) Figure 41. North America Oral Vaccine for Human Sales Share by Type (2021-2032) Figure 42. North America Oral Vaccine for Human Revenue Share by Application (2021-2032) Figure 43. North America Oral Vaccine for Human Sales Share by Application (2021-2032) Figure 44. North America Oral Vaccine for Human Revenue Share by Country (2021-2032) Figure 45. North America Oral Vaccine for Human Sales Share by Country (2021-2032) Figure 46. Europe Oral Vaccine for Human Revenue Share by Type (2021-2032) Figure 47. Europe Oral Vaccine for Human Sales Share by Type (2021-2032) Figure 48. Europe Oral Vaccine for Human Revenue Share by Application (2021-2032) Figure 49. Europe Oral Vaccine for Human Sales Share by Application (2021-2032) Figure 50. Europe Oral Vaccine for Human Revenue Share by Country (2021-2032) Figure 51. Europe Oral Vaccine for Human Sales Share by Country (2021-2032) Figure 52. China Oral Vaccine for Human Revenue Share by Type (2021-2032) Figure 53. China Oral Vaccine for Human Sales Share by Type (2021-2032) Figure 54. China Oral Vaccine for Human Revenue Share by Application (2021-2032) Figure 55. China Oral Vaccine for Human Sales Share by Application (2021-2032) Figure 56. Asia Oral Vaccine for Human Revenue Share by Type (2021-2032) Figure 57. Asia Oral Vaccine for Human Sales Share by Type (2021-2032) Figure 58. Asia Oral Vaccine for Human Revenue Share by Application (2021-2032) Figure 59. Asia Oral Vaccine for Human Sales Share by Application (2021-2032) Figure 60. Asia Oral Vaccine for Human Revenue Share by Country (2021-2032) Figure 61. Asia Oral Vaccine for Human Sales Share by Country (2021-2032) Figure 62. SAMEA Oral Vaccine for Human Revenue Share by Type (2021-2032) Figure 63. SAMEA Oral Vaccine for Human Sales Share by Type (2021-2032) Figure 64. SAMEA Oral Vaccine for Human Revenue Share by Application (2021-2032) Figure 65. SAMEA Oral Vaccine for Human Sales Share by Application (2021-2032) Figure 66. SAMEA Oral Vaccine for Human Revenue Share by Country (2021-2032) Figure 67. SAMEA Oral Vaccine for Human Sales Share by Country (2021-2032) Figure 68. Oral Vaccine for Human Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Oral Vaccine for Human Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Cholera Vaccine
  • Oral Polio Vaccine
  • Rotavirus Vaccine
  • Other
Applications
  • Public
  • Private
Companies covered
  • Bibcol
  • Bio-Med
  • EuBiologics
  • Halfkin Bio-Pharmaceuticals
  • Panacea Biotec Ltd
  • PaxVax
  • Serum Institute
  • Vabiotech
  • Valneva
  • Tiantan Biological
  • GSK
  • Merck
  • Sanofi
  • Shanghai United Cell
  • Lanzhou Institute

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Oral Vaccine for Human Market by Type
  3. 1.2.1 Global Oral Vaccine for Human Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Cholera Vaccine
  5. 1.2.3 Oral Polio Vaccine
  6. 1.2.4 Rotavirus Vaccine
  7. 1.2.5 Other
  8. 1.3 Oral Vaccine for Human Market by Application
  9. 1.3.1 Global Oral Vaccine for Human Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Public
  11. 1.3.3 Private
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Oral Vaccine for Human Market Dynamics
  1. 2.1 Oral Vaccine for Human Industry Trends
  2. 2.2 Oral Vaccine for Human Industry Drivers
  3. 2.3 Oral Vaccine for Human Industry Opportunities and Challenges
  4. 2.4 Oral Vaccine for Human Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Oral Vaccine for Human Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Oral Vaccine for Human Revenue by Region
  3. 3.2.1 Global Oral Vaccine for Human Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Oral Vaccine for Human Revenue by Region (2021-2026)
  5. 3.2.3 Global Oral Vaccine for Human Revenue by Region (2027-2032)
  6. 3.2.4 Global Oral Vaccine for Human Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Oral Vaccine for Human Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Oral Vaccine for Human Sales by Region
  9. 3.4.1 Global Oral Vaccine for Human Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Oral Vaccine for Human Sales by Region (2021-2026)
  11. 3.4.3 Global Oral Vaccine for Human Sales by Region (2027-2032)
  12. 3.4.4 Global Oral Vaccine for Human Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Oral Vaccine for Human Revenue by Manufacturers
  2. 4.1.1 Global Oral Vaccine for Human Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Oral Vaccine for Human Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Oral Vaccine for Human Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Oral Vaccine for Human Sales by Manufacturers
  6. 4.2.1 Global Oral Vaccine for Human Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Oral Vaccine for Human Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Oral Vaccine for Human Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Oral Vaccine for Human Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Oral Vaccine for Human Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Oral Vaccine for Human Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Oral Vaccine for Human Manufacturers, Product Type & Application
  13. 4.7 Global Oral Vaccine for Human Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Oral Vaccine for Human Market CR5 and HHI
  16. 4.8.2 2025 Oral Vaccine for Human Tier 1, Tier 2, and Tier 3
5 Oral Vaccine for Human Market by Type
  1. 5.1 Global Oral Vaccine for Human Revenue by Type
  2. 5.1.1 Global Oral Vaccine for Human Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Oral Vaccine for Human Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Oral Vaccine for Human Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Oral Vaccine for Human Sales by Type
  6. 5.2.1 Global Oral Vaccine for Human Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Oral Vaccine for Human Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Oral Vaccine for Human Sales Market Share by Type (2021-2032)
  9. 5.3 Global Oral Vaccine for Human Price by Type
6 Oral Vaccine for Human Market by Application
  1. 6.1 Global Oral Vaccine for Human Revenue by Application
  2. 6.1.1 Global Oral Vaccine for Human Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Oral Vaccine for Human Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Oral Vaccine for Human Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Oral Vaccine for Human Sales by Application
  6. 6.2.1 Global Oral Vaccine for Human Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Oral Vaccine for Human Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Oral Vaccine for Human Sales Market Share by Application (2021-2032)
  9. 6.3 Global Oral Vaccine for Human Price by Application
7 Company Profiles
  1. 7.1 Bibcol
  2. 7.1.1 Bibcol Company Information
  3. 7.1.2 Bibcol Business Overview
  4. 7.1.3 Bibcol Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Bibcol Oral Vaccine for Human Product Portfolio
  6. 7.1.5 Bibcol Recent Developments
  7. 7.2 Bio-Med
  8. 7.2.1 Bio-Med Company Information
  9. 7.2.2 Bio-Med Business Overview
  10. 7.2.3 Bio-Med Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Bio-Med Oral Vaccine for Human Product Portfolio
  12. 7.2.5 Bio-Med Recent Developments
  13. 7.3 EuBiologics
  14. 7.3.1 EuBiologics Company Information
  15. 7.3.2 EuBiologics Business Overview
  16. 7.3.3 EuBiologics Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 EuBiologics Oral Vaccine for Human Product Portfolio
  18. 7.3.5 EuBiologics Recent Developments
  19. 7.4 Halfkin Bio-Pharmaceuticals
  20. 7.4.1 Halfkin Bio-Pharmaceuticals Company Information
  21. 7.4.2 Halfkin Bio-Pharmaceuticals Business Overview
  22. 7.4.3 Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Product Portfolio
  24. 7.4.5 Halfkin Bio-Pharmaceuticals Recent Developments
  25. 7.5 Panacea Biotec Ltd
  26. 7.5.1 Panacea Biotec Ltd Company Information
  27. 7.5.2 Panacea Biotec Ltd Business Overview
  28. 7.5.3 Panacea Biotec Ltd Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Panacea Biotec Ltd Oral Vaccine for Human Product Portfolio
  30. 7.5.5 Panacea Biotec Ltd Recent Developments
  31. 7.6 PaxVax
  32. 7.6.1 PaxVax Company Information
  33. 7.6.2 PaxVax Business Overview
  34. 7.6.3 PaxVax Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 PaxVax Oral Vaccine for Human Product Portfolio
  36. 7.6.5 PaxVax Recent Developments
  37. 7.7 Serum Institute
  38. 7.7.1 Serum Institute Company Information
  39. 7.7.2 Serum Institute Business Overview
  40. 7.7.3 Serum Institute Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Serum Institute Oral Vaccine for Human Product Portfolio
  42. 7.7.5 Serum Institute Recent Developments
  43. 7.8 Vabiotech
  44. 7.8.1 Vabiotech Company Information
  45. 7.8.2 Vabiotech Business Overview
  46. 7.8.3 Vabiotech Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Vabiotech Oral Vaccine for Human Product Portfolio
  48. 7.8.5 Vabiotech Recent Developments
  49. 7.9 Valneva
  50. 7.9.1 Valneva Company Information
  51. 7.9.2 Valneva Business Overview
  52. 7.9.3 Valneva Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Valneva Oral Vaccine for Human Product Portfolio
  54. 7.9.5 Valneva Recent Developments
  55. 7.10 Tiantan Biological
  56. 7.10.1 Tiantan Biological Company Information
  57. 7.10.2 Tiantan Biological Business Overview
  58. 7.10.3 Tiantan Biological Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Tiantan Biological Oral Vaccine for Human Product Portfolio
  60. 7.10.5 Tiantan Biological Recent Developments
  61. 7.11 GSK
  62. 7.11.1 GSK Company Information
  63. 7.11.2 GSK Business Overview
  64. 7.11.3 GSK Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 GSK Oral Vaccine for Human Product Portfolio
  66. 7.11.5 GSK Recent Developments
  67. 7.12 Merck
  68. 7.12.1 Merck Company Information
  69. 7.12.2 Merck Business Overview
  70. 7.12.3 Merck Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Merck Oral Vaccine for Human Product Portfolio
  72. 7.12.5 Merck Recent Developments
  73. 7.13 Sanofi
  74. 7.13.1 Sanofi Company Information
  75. 7.13.2 Sanofi Business Overview
  76. 7.13.3 Sanofi Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Sanofi Oral Vaccine for Human Product Portfolio
  78. 7.13.5 Sanofi Recent Developments
  79. 7.14 Shanghai United Cell
  80. 7.14.1 Shanghai United Cell Company Information
  81. 7.14.2 Shanghai United Cell Business Overview
  82. 7.14.3 Shanghai United Cell Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Shanghai United Cell Oral Vaccine for Human Product Portfolio
  84. 7.14.5 Shanghai United Cell Recent Developments
  85. 7.15 Lanzhou Institute
  86. 7.15.1 Lanzhou Institute Company Information
  87. 7.15.2 Lanzhou Institute Business Overview
  88. 7.15.3 Lanzhou Institute Oral Vaccine for Human Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Lanzhou Institute Oral Vaccine for Human Product Portfolio
  90. 7.15.5 Lanzhou Institute Recent Developments
8 North America
  1. 8.1 North America Oral Vaccine for Human Market Size by Type
  2. 8.1.1 North America Oral Vaccine for Human Revenue by Type (2021-2032)
  3. 8.1.2 North America Oral Vaccine for Human Sales by Type (2021-2032)
  4. 8.1.3 North America Oral Vaccine for Human Price by Type (2021-2032)
  5. 8.2 North America Oral Vaccine for Human Market Size by Application
  6. 8.2.1 North America Oral Vaccine for Human Revenue by Application (2021-2032)
  7. 8.2.2 North America Oral Vaccine for Human Sales by Application (2021-2032)
  8. 8.2.3 North America Oral Vaccine for Human Price by Application (2021-2032)
  9. 8.3 North America Oral Vaccine for Human Market Size by Country
  10. 8.3.1 North America Oral Vaccine for Human Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Oral Vaccine for Human Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Oral Vaccine for Human Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Oral Vaccine for Human Market Size by Type
  2. 9.1.1 Europe Oral Vaccine for Human Revenue by Type (2021-2032)
  3. 9.1.2 Europe Oral Vaccine for Human Sales by Type (2021-2032)
  4. 9.1.3 Europe Oral Vaccine for Human Price by Type (2021-2032)
  5. 9.2 Europe Oral Vaccine for Human Market Size by Application
  6. 9.2.1 Europe Oral Vaccine for Human Revenue by Application (2021-2032)
  7. 9.2.2 Europe Oral Vaccine for Human Sales by Application (2021-2032)
  8. 9.2.3 Europe Oral Vaccine for Human Price by Application (2021-2032)
  9. 9.3 Europe Oral Vaccine for Human Market Size by Country
  10. 9.3.1 Europe Oral Vaccine for Human Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Oral Vaccine for Human Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Oral Vaccine for Human Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Oral Vaccine for Human Market Size by Type
  2. 10.1.1 China Oral Vaccine for Human Revenue by Type (2021-2032)
  3. 10.1.2 China Oral Vaccine for Human Sales by Type (2021-2032)
  4. 10.1.3 China Oral Vaccine for Human Price by Type (2021-2032)
  5. 10.2 China Oral Vaccine for Human Market Size by Application
  6. 10.2.1 China Oral Vaccine for Human Revenue by Application (2021-2032)
  7. 10.2.2 China Oral Vaccine for Human Sales by Application (2021-2032)
  8. 10.2.3 China Oral Vaccine for Human Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Oral Vaccine for Human Market Size by Type
  2. 11.1.1 Asia Oral Vaccine for Human Revenue by Type (2021-2032)
  3. 11.1.2 Asia Oral Vaccine for Human Sales by Type (2021-2032)
  4. 11.1.3 Asia Oral Vaccine for Human Price by Type (2021-2032)
  5. 11.2 Asia Oral Vaccine for Human Market Size by Application
  6. 11.2.1 Asia Oral Vaccine for Human Revenue by Application (2021-2032)
  7. 11.2.2 Asia Oral Vaccine for Human Sales by Application (2021-2032)
  8. 11.2.3 Asia Oral Vaccine for Human Price by Application (2021-2032)
  9. 11.3 Asia Oral Vaccine for Human Market Size by Country
  10. 11.3.1 Asia Oral Vaccine for Human Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Oral Vaccine for Human Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Oral Vaccine for Human Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Oral Vaccine for Human Market Size by Type
  2. 12.1.1 SAMEA Oral Vaccine for Human Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Oral Vaccine for Human Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Oral Vaccine for Human Price by Type (2021-2032)
  5. 12.2 SAMEA Oral Vaccine for Human Market Size by Application
  6. 12.2.1 SAMEA Oral Vaccine for Human Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Oral Vaccine for Human Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Oral Vaccine for Human Price by Application (2021-2032)
  9. 12.3 SAMEA Oral Vaccine for Human Market Size by Country
  10. 12.3.1 SAMEA Oral Vaccine for Human Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Oral Vaccine for Human Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Oral Vaccine for Human Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Oral Vaccine for Human Value Chain Analysis
  2. 13.1.1 Oral Vaccine for Human Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Oral Vaccine for Human Production Mode & Process
  6. 13.2 Oral Vaccine for Human Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Oral Vaccine for Human Distributors
  9. 13.2.3 Oral Vaccine for Human Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst